Navigation Links
Warren Lammert Joins IntelliMedix Board of Advisors
Date:2/27/2013

ATLANTA, Feb. 27, 2013 /PRNewswire-iReach/ -- IntelliMedix announced that Warren Lammert has been appointed to its Board. Lammert is the Chairman and co-founder of the Epilepsy Therapy Project and Epilepsy.com and is also a board member for FACES (Finding a Cure for Epilepsy and Seizures) at New York University.

"Warren brings an impressive track record accelerating innovation for new therapies in the field of epilepsy.  Warren's drive, passion and proven business acumen will be a great contribution to the Intellimedix team.  Warren will help us achieve our goal of finding cures for Dravet Syndrome, epilepsy and other neurological disorders. We are fortunate and excited to have him on board," said Daniel Fischer , President and CEO of Intellimedix.

Mr. Lammert is Founder, Principal and Chief Investment Officer of Granite Point Capital and has more than 18 years of investment industry experience. Prior to the formation of Granite Point Capital, he spent 14 years at Janus serving in several investment and senior management roles, including most recently, Portfolio Manager of the Janus Mercury Fund from its inception in 1993 until March 2003.

"I am thrilled to join with Intellimedix in working to build new approaches to drug discovery for Dravet Syndrome and other orphan and human diseases.  Jim Jacoby and Daniel Fischer have assembled a team with a remarkable breadth of expertise but what impresses me most is the range of effective collaborative partnerships that the Intellimedix team has built and nurtured around key emerging discovery technologies," said Warren Lammert .

Also sitting on the Board is Jim Jacoby , Chairman of the Board for IntelliMedix and CEO of Jacoby Development.

About IntelliMedix:

IntelliMedix was founded in early 2012 with the purpose of developing and applying novel technologies to accelerate the discovery of new therapies for neurological diseases and creating new approaches for personalized medicine. They employ cutting-edge technology that includes gene sequencing, in silico screening, optogenetics, synthetic biology, and high-throughput in vivo and in vitro models. The company's current focus is on developing new treatments for specific types of intractable epilepsy (e.g., Dravet Syndrome) and other neurological disorders. For more information, please visit http://www.intellimedix.com

Media Contact:

Joanna Morrison Intellimedix, 770-399-9930, jmorrison@intellimedix.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE IntelliMedix
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. FASEB joins President Obama in urging Congress to sustain investments in research and innovation
2. Book shows evolution that joins human and environmental sciences
3. Brazil joins global initiative for biodiversity data access
4. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
5. Brazil joins international marine research effort
6. Steve Fisher joins American Health IT LLC as VP of Operations
7. Hass Avocado Board study published in Food & Function journal
8. Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
9. JoVE establishes Librarian Advisory Board
10. Diving board sensors key to DNA detection
11. Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... --  Veridium , a leader in biometrics-based authentication ... James Stickland . Stickland, a seasoned financial ... served in senior executive roles for HSBC, JPMorgan ... a pipeline of venture capital and accelerating innovation ... as managing director of U.K.-based fintech firm Red ...
(Date:12/2/2016)... 1, 2016 The report "Biometric ... Future Technology (Iris Recognition System), Vehicle Type (Passenger ... Forecast to 2021", published by MarketsandMarkets, the market ... 2016, and is projected to grow to USD ... 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/8/2016)... to fuel Philadelphia,s innovative digital ... Southeastern Pennsylvania (" Ben Franklin "); Independence ... Cross; and Safeguard Scientifics ("Safeguard") (NYSE: SFE ... funding initiative over a four year period to grow ... burgeoning economic vitality in digital health, Ben Franklin ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. ... and expansion clinical trial for its lead drug candidate, AC0010, at the World ... trial was to determine the safety, antitumor activity, and recommended phase II dosage ...
Breaking Biology Technology: